Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.45 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.45 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.45 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | LTA4H | P09960 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6221979 | 0.90 | ITGB1 (0.53) | MAPK1ITGB1CYSLTR2CYSLTR1ITGA5 | |
| SCHEMBL6283666 | 0.89 | RAB9A (0.39) | CYSLTR2CYSLTR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6286907 | 0.82 | ELANE (0.46) | MAPK1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6289055 | 0.82 | ELANE (0.48) | CYSLTR2CYSLTR1PTPN1LTA4HFAAH | |
| SCHEMBL6286754 | 0.81 | ITGB1 (0.39) | ITGB1ITGA5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4831646 | 0.80 | ITGB1 (0.48) | ITGB1ITGA5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27750801 | 0.80 | HDAC3 (0.41) | MAPK1ITGB1ITGA5NPC1RAB9A | |
| SCHEMBL6222076 | 0.78 | LDHA (0.42) | ITGB1ITGA5NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL468297 | 0.77 | PTPRB (0.51) | CYP2C19 | |
| SCHEMBL468299 | 0.77 | PTPRB (0.51) | CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838453-B2 | Antagonist derivatives of the vitronectin receptor | AVENTIS PHARMA S.A. (FR) | 2005-01-04 | — | — | US | disclosed |
| US-20040225111-A1 | ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225111-A1 | ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR | ADGRF1, BDKRB1, ADGRE5 | MAPK1 1651/4885ITGB1 64/4885CYSLTR2 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.